F.T.C. v. Actavis, Inc.
Headline: Court allows FTC to challenge 'reverse payment' drug settlements, holding such brand-name payments to keep generics off market can sometimes violate antitrust law and change pay-for-delay review.
Holding: The Court held that payments from a patent holder to a potential generic to delay market entry can sometimes unlawfully reduce competition, and it allowed the FTC's antitrust lawsuit to proceed under a rule-of-reason review.
- Lets the FTC sue over pay-for-delay drug settlements.
- Makes cash payments to generics riskier for brand drug makers.
- Could speed entry of lower-cost generics if challenges succeed.
Summary
Background
A brand-name drug company (Solvay) sued several generic manufacturers (Actavis, Paddock, and Par) after they filed abbreviated applications saying Solvay's patent was invalid. The companies settled in 2006: the generics agreed to delay entering the market and Solvay agreed to pay millions ($12 million to Paddock; $60 million to Par; about $19–30 million annually to Actavis for nine years). The FTC sued in 2009, saying those payments were meant to share monopoly profits and block low-cost generics.
Reasoning
The Court asked whether a patentee's payment to keep a challenger out of the market can sometimes unreasonably harm competition. It held such "reverse payment" settlements can violate the antitrust laws in some circumstances. The Court emphasized special features of the drug-approval system (the paragraph IV challenge, a 180-day exclusivity for first filers, and the FDA's typical 30-month stay) that can make the first challenger uniquely valuable. Large unexplained payments may signal patent weakness and serve as a workable proxy for anticompetitive effect. The Court rejected a blanket immunity for these settlements and declined the FTC's request for a presumption of illegality; instead it requires a case-by-case rule-of-reason inquiry and remanded the case for further proceedings.
Real world impact
The decision lets the FTC pursue pay-for-delay claims against brand and generic firms and asks lower courts to weigh the size and justification of payments. It is not a final finding of illegality; settlements remain possible but may need noncash terms or clearer justifications. The ruling may make cash-for-delay deals riskier and could affect consumer drug prices.
Dissents or concurrances
A dissent led by the Chief Justice argued patents give a lawful right to exclude and that settlements within a patent's scope should not face antitrust liability; that view warned the ruling will discourage settlement and add litigation burden.
Ask about this case
Ask questions about the entire case, including all opinions (majority, concurrences, dissents).
What was the Court's main decision and reasoning?
How did the dissenting opinions differ from the majority?
What are the practical implications of this ruling?